#United States #New York #Class Action #Levi & Korsinsky #Skye Bioscience

Investors Urged to Join Class Action Lawsuit for Skye Bioscience, Inc.

In recent news, Levi & Korsinsky, LLP is reaching out to investors of Skye Bioscience, Inc. (NASDAQ: SKYE) regarding a class action lawsuit that has been filed to recover losses incurred due to alleged securities fraud. This development comes as a significant opportunity for affected investors who may seek justice for their financial losses.

Overview of the Class Action Lawsuit

The class action lawsuit is aimed at investors who suffered financially because of Skye Bioscience between November 4, 2024, and October 3, 2025. The lawsuit outlines that during this period, the company's management allegedly made misleading statements about its lead product candidate, nimacimab. These statements purportedly inflated the drug's clinical efficacy, regulatory, and commercial potential, leading investors to believe in an undue level of confidence in the company's prospects.

The specific allegations include claims that the company misrepresented the effectiveness of nimacimab, which is central to the company's commercial strategy. As the situation unfolded, it appears that the realities of the product's performance significantly deviated from the previously stated promises made by the company’s executives, contributing to the subsequent losses experienced by investors.

Call to Action for Affected Investors

Levi & Korsinsky is encouraging all investors who experienced losses during the relevant period to come forward and consider joining the class action. Important to note is that affected investors have until January 16, 2026, to request that the court appoint them as lead plaintiffs. However, even those who do not seek lead plaintiff status may still participate in any financial recovery without facing any out-of-pocket charges.

For those interested in pursuing this opportunity, they can find more information and submit their claims through a designated link provided by the law firm. It’s essential for investors to act promptly, as the window for joining the action has a firm deadline.

Why Choose Levi & Korsinsky?

Levi & Korsinsky has built a strong reputation over the past 20 years, recovering hundreds of millions of dollars for investors across various cases. With over 70 dedicated employees focused on complex securities litigation, the firm is well-equipped to handle such significant class action lawsuits. Its track record speaks volumes, having been recognized among the top securities litigation firms in the United States by ISS Securities Class Action Services.

The law firm assures potential class members that their participation in the lawsuit incurs no costs or obligations. Every investor's claim will be treated with the utmost care, and Levi & Korsinsky assures effective representation tailored to the needs of its clients.

Details on Contacting Levi & Korsinsky

Interested investors can reach out to Levi & Korsinsky, LLP, located at 33 Whitehall Street, 27th Floor, New York, NY 10004. For direct communication, investors can email Joseph E. Levi, Esq. at the provided address or contact the firm via phone.

In conclusion, investors in Skye Bioscience are urged to review their situation and consider the potential benefits of joining this class action lawsuit. With the firm backing of Levi & Korsinsky, affected individuals may have a path to recover some of their substantial losses due to this alleged fraud. Engaging in this collective legal action not only seeks individual recoveries but also holds corporate entities accountable to their shareholders for misleading and fraudulent practices.